Shares of Apellis Pharmaceuticals have been under pressure because investors are concerned about the sales trajectory of its vision preservation treatment, Syfovre. Although Syfovre has been ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.

But Syfovre has recovered ... The FDA approved Izervay in August of last year. Izervay’s label also includes warnings about endophthalmitis (inflammation), infections and intraocular pressure.

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its ...

Pegcetacoplan is already approved in paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) under the brand names Empaveli and Syfovre ... In an open-label period of the phase ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.